Discover this publication on A novel VWF-associated thrombolytic agent, by Frank W. G. Leebeek, in which in vivo studies were performed by STROK@LLIANCE team on our MCA occlusion by FECl3 application in vivo model. Published in Blood (2022) 140 (26): 2770–2771. December 29, 2022.
Read the full article: DOI: https://doi.org/10.1182/blood.2022018024
Connected content: VWF-targeted thrombolysis to overcome rh-tPA resistance in experimental murine ischemic stroke models
Keywords: ischemic stroke, microlyse, thrombolytic agent, fibrin-rich thrombi, platelet-rich thrombi, cerebral reperfusion.
Authors: Frank W. G. Leebeek
Affiliated:
- 1. Erasmus MC, University Medical Center Rotterdam
ABSTRACT:
First results on Microlyse, a novel agent in acute ischemic stroke
In this issue of Blood, van Moorsel et al report the first results on Microlyse, a novel agent with treatment potential that uses a new target to lyse pathologic thrombi in acute ischemic stroke.1 In a brief report, they present their mouse studies of experimentally induced stroke treated with either Microlyse, recombinant human tissue-plasminogen activator (rtPA), or vehicle. They show that Microlyse degraded thrombin-induced fibrin-rich thrombi in the middle cerebral artery (MCA), with results comparable to those obtained by rtPA infusion.
Microlyse, von Willebrand factor (VWF) and plasminogen activation
Recombinant human tissue plasminogen activator (rh-tPA) is an important thrombolytic agent for treatment of acute ischemic stroke. It requires fibrin binding for plasminogen activation. In contrast, Microlyse, a novel thrombolytic agent, requires von Willebrand factor (VWF) binding for plasminogen activation.
